Shenzhen Salubris Pharmaceuticals Co., Ltd. (SHE:002294)

Market Cap	47.71B
Revenue (ttm)	3.98B
Net Income (ttm)	601.63M
Shares Out	1.11B
EPS (ttm)	0.54
PE Ratio	79.26
Forward PE	69.41
Dividend	0.50 (1.18%)
Ex-Dividend Date	May 14, 2025

Volume	8,113,956
Average Volume	11,578,921
Open	37.90
Previous Close	42.26
Day's Range	37.90 - 43.43
52-Week Range	25.51 - 43.58
Beta	0.74
RSI	66.25
Earnings Date	Aug 26, 2025

About SHE:002294

Shenzhen Salubris Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of medicines and medical devices in China. The company offers drugs for various therapeutic fields, such as thrombosis, hypertension and related diseases, osteoporosis, and infections, as well as anti-osteolysis, antiallergic, antiepileptic, and antidepressant medicines. It also provides interventional medical devices for therapy of cardiovascular and cerebrovascular diseases, peripheral blood vessels, structural heart diseases, electrophysiol...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 1998
• Employees: 3,596
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002294

Financial Performance

In 2024, SHE:002294's revenue was 4.01 billion, an increase of 19.22% compared to the previous year's 3.37 billion. Earnings were 601.57 million, an increase of 3.71%.